Live-News • Jun 30
Park Ha Biological Technology Teams Up With Amazon for North American Personal Care Market Entry Park Ha Biological Technology has begun cooperating with Amazon North America to enter the North American personal care market. This includes work on store qualification registration, Amazon brand registry, regulatory compliance and localized product strategies, ahead of launching a flagship storefront on Amazon’s marketplace.
Management frames this cooperation as part of Park Ha Biological Technology’s global expansion plans, aiming to widen growth opportunities and build brand recognition in a large new geography through a platform-based entry approach.
Park Ha Biological Technology shares trade at US$1.17, with the stock down 86.2% year to date, indicating that the market has so far priced the company cautiously despite its expansion efforts.
This Amazon cooperation gives Park Ha Biological Technology a defined route into a sizeable consumer market. However, execution on compliance, branding and local product fit will be crucial, and investors will likely focus on evidence of actual sales traction rather than the announcement alone. Ankündigung • Jun 16
Park Ha Biological Technology Co., Ltd. has completed a Follow-on Equity Offering in the amount of $1.999996 million. Park Ha Biological Technology Co., Ltd. has completed a Follow-on Equity Offering in the amount of $1.999996 million.
Security Name: Class A Ordinary Shares
Security Type: Common Stock
Securities Offered: 1,133,332
Price\Range: $1.5
Discount Per Security: $0.12
Security Name: Pre-Funded Warrant.
Security Type: Equity Warrant
Securities Offered: 200,000
Price\Range: $1.49999
Discount Per Security: $0.119999
Transaction Features: Registered Direct Offering Ankündigung • Jun 14
Park Ha Biological Technology Co., Ltd. has filed a Follow-on Equity Offering. Park Ha Biological Technology Co., Ltd. has filed a Follow-on Equity Offering.
Security Name: Class A Ordinary Shares
Security Type: Common Stock
Securities Offered: 1,133,332
Price\Range: $1.5
Security Name: Pre-Funded Warrant.
Security Type: Equity Warrant
Securities Offered: 200,000
Transaction Features: Registered Direct Offering New Risk • Jun 08
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 44% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (44% average weekly change). Earnings have declined by 84% per year over the past 5 years. Shareholders have been substantially diluted in the past year (297% increase in shares outstanding). Market cap is less than US$10m (US$2.22m market cap). Minor Risk Revenue is less than US$5m (US$2.5m revenue). Reported Earnings • Mar 04
Full year 2025 earnings released: US$41.38 loss per share (vs US$0.96 profit in FY 2024) Full year 2025 results: US$41.38 loss per share (down from US$0.96 profit in FY 2024). Revenue: US$2.52m (up 6.0% from FY 2024). Net loss: US$24.4m (down US$24.8m from profit in FY 2024). New Risk • Feb 02
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 111% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 89% per year over the past 5 years. Shareholders have been substantially diluted in the past year (111% increase in shares outstanding). Market cap is less than US$10m (US$4.91m market cap). Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Revenue is less than US$5m (US$2.8m revenue). Ankündigung • Jan 29
Park Ha Biological Technology Co., Ltd. has completed a Composite Units Offering in the amount of $2.45 million. Park Ha Biological Technology Co., Ltd. has completed a Composite Units Offering in the amount of $2.45 million.
Security Name: Units
Security Type: Equity/Derivative Unit
Securities Offered: 21,875,000
Price\Range: $0.112
Discount Per Security: $0.008 New Risk • Jan 27
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 89% per year over the past 5 years. Market cap is less than US$10m (US$4.95m market cap). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Shareholders have been diluted in the past year (28% increase in shares outstanding). Revenue is less than US$5m (US$2.8m revenue). Ankündigung • Sep 20
Park Ha Biological Technology Co., Ltd. has filed a Follow-on Equity Offering. Park Ha Biological Technology Co., Ltd. has filed a Follow-on Equity Offering.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 11,428,571
Security Name: Warrants
Security Type: Equity Warrant
Securities Offered: 11,428,571 Ankündigung • Sep 19
Park Ha Biological Technology Co., Ltd., Annual General Meeting, Oct 03, 2025 Park Ha Biological Technology Co., Ltd., Annual General Meeting, Oct 03, 2025, at 10:00 China Standard Time. Location: 901, building c phase 2, wuxi international life science innovation campus, 196 jinghui east road xinwu district, wuxi China Reported Earnings • Aug 27
First half 2025 earnings released: US$0.74 loss per share (vs US$0.002 profit in 1H 2024) First half 2025 results: US$0.74 loss per share (down from US$0.002 profit in 1H 2024). Revenue: US$1.24m (up 45% from 1H 2024). Net loss: US$19.8m (down US$19.9m from profit in 1H 2024). New Risk • Jul 09
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: US$78.9m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (29% average weekly change). Revenue has declined by 3.1% over the past year. Minor Risks Profit margins are more than 30% lower than last year (20% net profit margin). Revenue is less than US$5m (US$2.4m revenue). Market cap is less than US$100m (US$78.9m market cap). Reported Earnings • Feb 25
Full year 2024 earnings released: EPS: US$0.019 (vs US$0.034 in FY 2023) Full year 2024 results: EPS: US$0.019 (down from US$0.034 in FY 2023). Revenue: US$2.38m (down 3.1% from FY 2023). Net income: US$478.6k (down 44% from FY 2023). Profit margin: 20% (down from 35% in FY 2023). The decrease in margin was primarily driven by higher expenses. New Risk • Jan 12
New major risk - Financial data availability The company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Shares are highly illiquid. Ankündigung • Jan 08
Park Ha Biological Technology Co., Ltd. Announces Appointment of Da Yang as an Independent Director On January 7, 2025, the Board approved the appointment of Da Yang (Mr. Yang) as an independent director of the Park Ha Biological Technology Co., Ltd., effective January 7, 2025. Mr. Yang does not have a family relationship with any director or executive officer of the Company and has not been involved in any transaction with the Company during the past two years that would require disclosure under Item 404(a) of Regulation S-K. The biography for Mr. Yang is set forth below: Mr. Yang, aged 37, is an independent director of the Company. Mr. Yang has had many years of experience in sales and marketing. Mr. Yang served as the market director in Beijing New Space Technology Co., Ltd. since January 2021. From June 2017 to June 2020, Mr. Yang was a senior marketing manager in Gome Insurance Brokers Limited. From October 2015 to August 2016, Mr. Yang was an assistant to the general manager in Dade Liangju Trading (Beijing) Co., Ltd. Mr. Yang obtained his college degree in music performance (music) from Capital Normal University in 2008. The Board has determined that Mr. Yang qualifies as an independent director under the rules of the Nasdaq Stock Market LLC. In connection with his appointment, Mr. Yang will be entitled to receive the Company’s standard compensation provided to independent directors, pursuant to the independent director agreement between Mr. Yang and the Company. Ankündigung • Dec 27
Park Ha Biological Technology Co., Ltd. has completed an IPO in the amount of $4.8 million. Park Ha Biological Technology Co., Ltd. has completed an IPO in the amount of $4.8 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 1,200,000
Price\Range: $4
Discount Per Security: $0.28 
